We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+10.16%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.87B
AUM Growth
+$199M
Cap. Flow
+$56.8M
Cap. Flow %
1.98%
Top 10 Hldgs %
71.68%
Holding
83
New
11
Increased
14
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$92.5M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$61.6M
3
RCUS icon
Arcus Biosciences
RCUS
+$55.6M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$34.5M
5
ALEC icon
Alector
ALEC
+$21.1M

Top Sells

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$104M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$35.3M
3
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$28.9M
4
NRIX icon
Nurix Therapeutics
NRIX
+$26M
5
KYMR icon
Kymera Therapeutics
KYMR
+$25.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.8%
2 Miscellaneous 1.52%
3 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
1
Prothena Corp
PRTA
$479M
$804M 27.96%
11,284,280
– –
MORF
2
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$224M 7.79%
3,951,566
– –
ANAB icon
3
AnaptysBio
ANAB
$1.67B
$204M 7.1%
7,521,024
– –
RCUS icon
4
Arcus Biosciences
RCUS
$3.72B
$179M 6.21%
5,122,359
+1,787,112
+54% +$55.6M
XNCR icon
5
Xencor
XNCR
$1.94B
$160M 5.57%
4,906,106
– –
NUVB icon
6
Nuvation Bio
NUVB
$2.34B
$136M 4.74%
13,711,517
– –
ALEC icon
7
Alector
ALEC
$261M
$114M 3.97%
4,994,970
+752,336
+18% +$21.1M
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$82.1M 2.86%
464,298
– –
LKFT
9
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$82M 2.85%
+1,558,749
New +$92.5M
STTK icon
10
Shattuck Labs
STTK
$707M
$75.6M 2.63%
3,709,072
+390,662
+12% +$8.36M
ORIC icon
11
Oric Pharmaceuticals
ORIC
$1.37B
$72.5M 2.52%
3,468,944
+376,726
+12% +$7.64M
KURA icon
12
Kura Oncology
KURA
$1.13B
$69.8M 2.43%
3,724,437
– –
RNAM
13
DELISTED
Avidity Biosciences
RNAM
$68M 2.36%
2,759,505
+655,555
+31% +$14.2M
GRTS
14
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$60.1M 2.09%
5,560,748
+2,139,461
+63% +$19.5M
RLAY icon
15
Relay Therapeutics
RLAY
$4.11B
$43.7M 1.52%
1,385,276
-3,102,500
-69% -$104M
ITOS
16
DELISTED
iTeos Therapeutics
ITOS
$35.2M 1.22%
1,303,157
+267,293
+26% +$6.99M
NRIX icon
17
Nurix Therapeutics
NRIX
$2.72B
$33.8M 1.17%
1,126,640
-841,310
-43% -$26M
JANX icon
18
Janux Therapeutics
JANX
$1.1B
$30.5M 1.06%
1,411,975
– –
DSGN icon
19
Design Therapeutics
DSGN
$946M
$27.4M 0.95%
1,863,098
+603,079
+48% +$10M
BPMC
20
CALL
DELISTED
Blueprint Medicines
BPMC
$25.9M 0.9%
+250,000
New +$23.3M
PTGX icon
21
Protagonist Therapeutics
PTGX
$9.34B
$25.6M 0.89%
+1,443,800
New +$61.6M
DRNA
22
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$25.2M 0.88%
+1,249,812
New +$34.5M
AKUS
23
DELISTED
Akouos Inc
AKUS
$22.9M 0.8%
1,975,984
– –
SLDB icon
24
Solid Biosciences
SLDB
$1.05B
$22M 0.77%
613,513
– –
EWTX icon
25
Edgewise Therapeutics
EWTX
$4.64B
$21.2M 0.74%
1,279,175
+55,000
+4% +$995K
1
2 3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2021 Portfolio in Review

As of Q3 2021, EcoR1 Capital held 83 positions worth $2.87B, up 7.4% from $2.68B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital's Q3 2021 filing shows 11 new, 14 increased, 8 reduced and 12 closed positions. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 1,558,749 shares worth $82M. The largest sale was Relay Therapeutics, an estimated $104M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

  • EcoR1 Capital's largest Q3 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 1,558,749 shares worth $82M.
  • EcoR1 Capital added most to Arcus Biosciences in Q3 2021, an estimated $55.6M increase.
  • EcoR1 Capital's biggest Q3 2021 reduction was Relay Therapeutics, cutting an estimated $104M.
  • EcoR1 Capital fully exited Translate Bio, Inc. Common Stock in Q3 2021, selling an estimated $28.9M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $2.87B portfolio in Q3 2021.
  • EcoR1 Capital opened 11 new positions and closed 12 in Q3 2021.
  • EcoR1 Capital's portfolio value rose 7.4% quarter-over-quarter to $2.87B.

Based on EcoR1 Capital's 13F filing for Q3 2021, filed 15 Nov 2021.